About EvolveImmune
EvolveImmune is a company based in Branford (United States) founded in 2019 by Charles Fuchs.. EvolveImmune has raised $92 million across 3 funding rounds from investors including Pfizer, Takeda Pharmaceuticals and Bristol-Myers Squibb. EvolveImmune offers products and services including EVOLVE104 and EVOLVE Platform.
- Headquarter Branford, United States
- Founders Charles Fuchs
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Evolveimmune Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$92 M (USD)
in 3 rounds
-
Latest Funding Round
$20 M (USD), Series B
Oct 22, 2024
-
Investors
Pfizer
& 7 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of EvolveImmune
EvolveImmune offers a comprehensive portfolio of products and services, including EVOLVE104 and EVOLVE Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
A trispecific T cell engager with integrated CD2 costimulation is developed to treat cancer by addressing cell resistance.
The platform is utilized for creating therapeutics that overcome resistance in current immunotherapies for cancer.
Unlock access to complete
Unlock access to complete
Funding Insights of EvolveImmune
EvolveImmune has successfully raised a total of $92M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $20 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series B — $20.0M
-
First Round
First Round
(01 Jan 2020)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2024 | Amount | Series B - EvolveImmune | Valuation |
investors |
|
| Dec, 2023 | Amount | Series B - EvolveImmune | Valuation | Bristol-Myers Squibb , Pfizer | |
| Jan, 2020 | Amount | Series A - EvolveImmune | Valuation | Pfizer Ventures , Solasta Ventures |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in EvolveImmune
EvolveImmune has secured backing from 8 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, Takeda Pharmaceuticals and Bristol-Myers Squibb. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital investments are managed by Pfizer-backed firm since 2004.
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by EvolveImmune
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - EvolveImmune
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Evolveimmune Comparisons
Competitors of EvolveImmune
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about EvolveImmune
When was EvolveImmune founded?
EvolveImmune was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Where is EvolveImmune located?
EvolveImmune is headquartered in Branford, United States. It is registered at Branford, Connecticut, United States.
Is EvolveImmune a funded company?
EvolveImmune is a funded company, having raised a total of $92M across 3 funding rounds to date. The company's 1st funding round was a Series A of $35M, raised on Jan 01, 2020.
What does EvolveImmune do?
EvolveImmune was established in 2019 in Branford, United States, as a research laboratory. Focus is placed on identifying novel therapeutic targets within immunotherapy. Operations involve scientific investigations into immune system mechanisms for potential treatments. The biotechnology sector is served through targeted discovery efforts, with activities centered in the United States. Contributions are made to advancing medical research in immune-based therapies.
What products or services does EvolveImmune offer?
EvolveImmune offers EVOLVE104 and EVOLVE Platform.
Who are EvolveImmune's investors?
EvolveImmune has 8 investors. Key investors include Pfizer, Takeda Pharmaceuticals, Bristol-Myers Squibb, Pfizer Ventures, and Elm Street Ventures.